Latest Headlines

Latest Headlines

Report: Bristol exec nabbed on insider trading charge

Bristol-Myers Squibb was having a very bad day today. As its stock was falling in the wake of the news that its $2.5 billion hep C drug may not be worth $2.50, one of its executives was charged with insider trading ahead of three key acquisitions, according to a report from Bloomberg.

ZymoGenetics turns in stellar IIa data on melanoma program

Bristol-Myers Squibb landed a big bonus from ZymoGenetics this morning. Just weeks after the Seattle-based biotech agreed to an $885 million buyout offer, the smaller biotech announced some

BMS forges $885M deal to buy ZymoGenetics

Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million, snaring its development partner on a mid-stage hepatitis C program along with a pipeline that includes new

ZymoGenetics forges $182M antibody deal with Novo

Antibodies make up one of the hottest markets for new therapeutics. For example, Novo Nordisk is slapping down $24 million in upfront cash and promising up to $157.5 million more to ZymoGenetics for

ZymoGenetics halts immunology work, cuts 52 jobs

ZymoGenetics is cutting all of its immunology work along with 15 percent of its jobs, or 52 positions. That's in addition to the 161 jobs the developer cut in April when it decided to bow out of the

Investigators suspend trial of ZymoGenetics' drug

There's more bad news for ZymoGenetics' experimental drug atacicept this morning. The developer (ZGEN) announced that Merck Serono has decided to suspend clinical trials of the drug as a treatment

ZymoGenetics, Immunomedics shares rise on HGS lupus data

The prospect of a new lupus drug hitting the market after decades without a new treatment for the autoimmune disease obviously has Human Genome Sciences investors excited--the company's stock has

ZymoGenetics chops 161 jobs, narrows R&D

Seattle-based ZymoGenetics is taking out the budget axe and chopping 161 jobs, one third of its workforce, as the biotech restructures its R&D effort in order to reduce costs by about $30 million

ZymoGenetics scores mega-deal with BMS

Seattle-based ZymoGenetics scored a blockbuster deal with Bristol-Myers Squibb for its hepatitis C therapy PEG-interferon lambda. The biotech's stock soared 35 percent on the news that it would

ZymoGenetics shares plunge after risks halt trial

Shares of ZymoGenetics were battered yesterday after the company announced that Merck KGaA had discontinued a trial on a partnered therapeutic after researchers noted a high risk of infection for